Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2005
11/22/2005US6968226 Method and system for terminating an atrial arrhythmia
11/22/2005US6967218 Pravastatin pharmaceutical formulations and methods of their use
11/22/2005US6967216 Neuropeptide Y receptor modulators; treating eating disorders
11/22/2005US6967214 Inhibitors of IMPDH enzyme
11/22/2005US6967210 Multiple sclerosis, brain disorders, analgesics
11/22/2005US6967204 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
11/22/2005US6967197 Also used in production of tumor necrosis factor alpha
11/22/2005US6967023 solidifying agent consists of a long chain fatty alcohol having at least 15 carbon atoms in its backbone and a fatty acid having at least 18 carbons in its backbone; carrier is semi-solid at rest and liquefies upon application of shear forces
11/22/2005CA2433181C Amlodipine hemifumarate
11/22/2005CA2068066C Herpesvirus particles and vaccine
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005108370A1 Benzene compounds
11/17/2005WO2005107783A1 Food containing extract from bark of pine
11/17/2005WO2005107778A1 Body fat reducing preparation
11/17/2005WO2005107737A1 Antifatigue composition
11/17/2005WO2005107731A1 Remedies containing vitamin k2 as the active ingredient
11/17/2005WO2005107498A1 Food containing polyphenol
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256326 Process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
11/17/2005US20050256311 Pyrimidine compounds
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256299 Vaccines
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256198 2-[(4-{3-[benzyl(hexyl)amino]-3-oxopropyl}phenoxy)methyl]benzoic acid;peroxisome proliferator-activated receptors alfa agonist; antidiabetic, hypotensive agent; obesity, elevated VLDL (Very Low Density Lipoproteins) and reduced HDL (High Density Lipoprotein) concentrations
11/17/2005US20050256194 Denaturants for sympathomimetic amine salts
11/17/2005US20050256167 Preparation and use of imidazole derivatives for treatment of obesity
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256142 New purine derivatives
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
11/17/2005US20050256086 Fosinopril formulation
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256033 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255182 Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
11/17/2005US20050255169 Adjuvant containing xenon
11/17/2005US20050255168 Cerebral protection with a gas comprising xenon
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255111 Use of an inhibitor or antagonist against tissue factor
11/17/2005US20050255096 Combination treatment for acute myocardial infarction
11/17/2005CA2566431A1 Process for the preparation of telmisartan
11/17/2005CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2566083A1 Antifatigue composition
11/17/2005CA2565630A1 Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
11/17/2005CA2565616A1 Pyrroloquinoline quinone drugs for treatment of cardiac injury
11/17/2005CA2564033A1 A method for the prevention of thromboembolic disorders
11/17/2005CA2564025A1 A method for the treatment or prevention of cardiac hypertrophy
11/17/2005CA2562287A1 Sustained-release oral molsidomine composition for treating atherosclerosis
11/17/2005CA2561141A1 Methods for treating blood disorders with nitric oxide donor compounds
11/16/2005EP1595951A1 Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1595573A2 Stent comprising manipulators of nitrosative stress to reduce restenosis
11/16/2005EP1595545A1 Blood-vessel-growth promoter
11/16/2005EP1595540A1 Composition containing an angiotensin II receptor antagonist and a diuretic and its use for the treatment of hypertension
11/16/2005EP1594845A2 Benzene acetamide compounds useful as serine protease inhibitors
11/16/2005EP1594841A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
11/16/2005EP1594527A2 Vegf-b and pdgf modulation of stem cells
11/16/2005EP1594517A2 Methods and compositions for the treatment of gastrointestinal disorders
11/16/2005EP1594510A2 Method and kit for reducing the symptoms of peripheral vascular disease
11/16/2005EP1594505A2 Phenylglycine derivatives useful as serine protease inhibitors
11/16/2005EP1594503A2 Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
11/16/2005EP1594502A1 4- (2,4-dichloro-5-methoxyphenyl)amino -6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
11/16/2005EP1594492A2 Novel inhibitors of formation of advanced glycation endproducts (ages)
11/16/2005EP1594486A2 Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same
11/16/2005EP1594480A1 Method to treat chronic heart failure and/or elevated cholesterol levels
11/16/2005EP1492795B1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/16/2005EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha
11/16/2005EP1476429B1 Novel pyridine- and quinoline-derivatives
11/16/2005EP1463823A4 Methods of increasing endogenous erythropoietin (epo)
11/16/2005EP1409488B1 Imidazo-triazine derivatives as ligands for gaba receptors
11/16/2005EP1379516B1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1357955B1 Drug delivery from stents
11/16/2005EP1350516B1 Use of compositions for preventing or ameliorating multiple risk factor syndrome
11/16/2005EP1347982B1 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
11/16/2005EP1257550B1 Platelet adp receptor inhibitors
11/16/2005EP1222191B1 Benzodiazepin derivatives, the production and use thereof
11/16/2005EP1222182B1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
11/16/2005EP1218374B1 Pharmaceutically active sulfonamide derivatives
11/16/2005EP1218017B1 Combination of a statin and ex-vivo treated blood for treating atherosclerosis
11/16/2005EP1213353B1 Peptide leukotriene receptor
11/16/2005EP1131090B1 Use of paraoxanase-1 (pon-1) to decrease atheroma formation and hypercholesterolemia
11/16/2005EP1114052B1 4-aminopyrrolopyrimidines as kinase inhibitors
11/16/2005EP0876395B1 Inhibitors of interleukin-1beta converting enzyme
11/16/2005EP0832232B1 Kunitz type plasma kallikrein inhibitors
11/16/2005CN1697878A Novel peptides having cAMP producing activity
11/16/2005CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists
11/16/2005CN1697830A 嘧啶衍生物 Pyrimidine derivatives
11/16/2005CN1697828A New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/16/2005CN1697655A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/16/2005CN1227259C Propanolamine derivs. linked with bile acid used for treating disorders of lipid metabolism
11/16/2005CN1227248C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
11/16/2005CN1227245C Food product and producing method
1 ... 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 ... 1595